HBV Treatment 2019

 

19HBV_TX_Banner_720px

HBV_Tx19_LAUNCH_web-button

About the Program:

Target Audience:

This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HCV infection.

Back to Top

Learning Objectives:

Upon completion of the program, participants should be able to:

  • Discuss how the hepatitis B virus (HBV) is transmitted in various populations
  • Describe the symptoms of HBV infection
  • Identify the long-term risk and consequences of untreated HBV infection
  • Review the various major treatment guidelines for the diagnosis and management of patients with HBV infection
  • Discuss the relative advantages and disadvantages of various antiviral treatments available for patients with HBV infection
  • Describe the treatment of special populations of patients with HBV infection

Release Date: June 21, 2019

Expiration Date: June 21, 2020

Estimated time to complete each Module: 30 minutes 

Media: Web

Back to Top

Faculty:

Douglas T. Dieterich, MD
Professor of Medicine and,
Director of CME
Department of Medicine 
Director of Outpatient Hepatology
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York 

Paul J. Gaglio, MD, FACP, AGAF, FAASLD
Director; Hepatology Outreach Center for Liver Disease and Transplantation
Professor of Medicine (in Surgery)
New York-Presbyterian Hospital
Columbia University Medical Center
New York, NY

Paul Kwo, MD
Director of Hepatology
Professor of Medicine
Stanford University School of Medicine
Palo Alto, California 

Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Back to Top

Joint Accreditation Statement:

Jointly-Accredited-Provider-TM_1000x636  In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Back to Top

Credit Designation:

Module 1 (HBV Epidemiology and Prevention):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 2 (Natural History of Hepatitis B):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 3 (HBV Management and Treatment): 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 4 (HBV Unique Clinical Situations):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Doug Dieterich, MD:
  • Consulting Fees: Gilead, Arbutus
Paul Gaglio, MD:
  • Consulting Fees: Gilead, Abbvie, Salix, Dova
Paul Kwo, MD:
  • Consulting Fees: Abbvie, Gilead, Quest
  • Contracted Research: Abbvie, BMS, Gilead, Assembly
  • DSMB: Janssen
Mark Sulkowski, MD:
  • Consulting Fees: Abbott, Gilead, Arbutus
  • Contracted Research:Assembly, Bio, Gilead

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

Back to Top

Instructions for Participation and Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period, June 21, 2019 through June 21, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 14173. Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Back to Top

Computer System Requirements

This program requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable version of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player and Real Networks Real One Player.

Back to Top

 

 

 

PIM_small

For CME Accreditation Questions, please click HERE

VE logo 300px 

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs 


  Jointly provided by the Postgraduate Institute for Medicine and ViralEd, Inc.


ViralEd, LLC

http://www.viraled.com/modules/info/hbv_treatment_2019.html